Climb Bio, Inc. Files 8-K

Ticker: CLYM · Form: 8-K · Filed: Sep 29, 2025 · CIK: 1768446

Sentiment: neutral

Topics: 8-K, corporate-filing, pharmaceutical

TL;DR

Climb Bio (fka Eliem) filed an 8-K on 9/29/25. Nothing major disclosed yet.

AI Summary

Climb Bio, Inc. (formerly Eliem Therapeutics, Inc.) filed an 8-K on September 29, 2025, reporting on other events and financial statements. The company, incorporated in Delaware, operates in the Pharmaceutical Preparations sector and is located in Wellesley Hills, MA.

Why It Matters

This filing indicates Climb Bio, Inc. is providing updates on its corporate activities and financial status to the SEC.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for reporting events and financial statements, with no immediate negative or positive news disclosed.

Key Numbers

Key Players & Entities

FAQ

What specific 'Other Events' are being reported by Climb Bio, Inc. in this 8-K?

The filing indicates 'Other Events' are being reported, but the specific details of these events are not provided in the excerpt.

What is the significance of the former company name, Eliem Therapeutics, Inc.?

Climb Bio, Inc. was formerly known as Eliem Therapeutics, Inc., with a name change date of February 19, 2019.

What is the primary business of Climb Bio, Inc.?

Climb Bio, Inc. operates in the Pharmaceutical Preparations sector, with the Standard Industrial Classification code 2834.

When was this 8-K filing submitted?

This 8-K filing was submitted as of September 29, 2025.

Where are Climb Bio, Inc.'s principal executive offices located?

Climb Bio, Inc.'s principal executive offices are located at 20 William Street, Suite 145, Wellesley Hills, Massachusetts 02481.

Filing Stats: 1,349 words · 5 min read · ~4 pages · Grade level 14.6 · Accepted 2025-09-29 07:48:40

Key Financial Figures

Filing Documents

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding: future expectations, plans and prospects for the Company; expectations regarding the therapeutic benefits, clinical potential and clinical development of budoprutug and CLYM116; expectations regarding the timing of submitting an investigational new drug application or clinical trial application submission for CLYM116; the anticipated timelines for initiating a clinical trial of CLYM116 and reporting initial data; the anticipated benefits of the Company's license agreement with Beijing Mabworks Biotech Co., Ltd. ("Mabworks"); the sufficiency of the Company's cash resources for the period anticipated; and other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would," "will," "working" and similar expressions. Forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. The Company may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. These risks and uncertainties include, but are not limited to, important risks and uncertainties associated with: the ability of the Company to timely and successfully achieve or recognize the anticipated benefits of its acquisition of Tenet Medicines, Inc. and its license agreement with Mabworks; changes in applicable laws or regulation; the possibility that the Company may be adversely affected by other economic, business and/or com

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 99.1 Press Release, dated September 29, 2025 99.2 Presentation, dated September 29, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Climb Bio, Inc. Date: September 29, 2025 By: /s/ Aoife Brennan Aoife Brennan, M.B., Ch.B. President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing